
Mounjaro prishöjning lämnar brittiska patienter med stora räkningar
Granskad av Dr Colin Tidy, MRCGPFörfattad av Thomas Andrew Porteus, MBCSUrsprungligen publicerad 14 Aug 2025
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
If you buy the weight-loss medicine Mounjaro privately in the UK you may see a steep price increase from September. The change will not affect you if you get your medicine from the NHS.
Here we show what are the alternatives and what you need to think about if you change or stop taking medicines.
Explore medical weight management options
Get expert healthcare advice from the comfort of home. Complete a quick online consultation, available 24/7, with your request reviewed by a UK-registered clinician. Next day delivery available on eligible treatments.
Videoval för HälsonyheterVideobibliotek
What is Mounjaro and who uses it?
Mounjaro is the brand name for tirzepatide, a medicine that mimics hormones in your body to help control blood sugar and reduce appetite. It’s given by weekly injection and is licensed for type 2 diabetes and for weight loss and weight management in adults aged 18 and over.
Mounjaro is authorised for adult patients with a BMI of 30 or more (obesity), as well as those with a BMI between 27-30 (overweight) who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.
At the moment, more than 1.5 million people in the UK use weight-loss medicines. Mounjaro is the most popular. Around 9 out of 10 people getting it do so privately, often through online providers or high-street pharmacies.
Vad förändras?
From September, the manufacturer Eli Lilly is putting up the price. The highest dose, which is one of the most commonly used, will increase from around £122 to £330 per month - a rise of around 170%. Lower doses will also cost more, but the increases will be smaller.
These changes only apply to people buying the drug privately and not those getting the medicine on the NHS. NHS prices are agreed in separate deals and will stay the same.
Why is this happening?
Eli Lilly says the current private price in the UK was always temporary. The company initially set it low to help people access the drug earlier. Now that more research is available, and the drug has been launched in more countries, they say the UK price needs to match what other countries pay.
The manufacturer also said the price change was partly influenced by the global debate around medicine costs. In the US, President Donald Trump has suggested linking medicine prices to what’s paid in other countries. Eli Lilly says it supports fair pricing, but does not think that approach works in practice.
What are the alternatives?
Wegovy is a different injectable weight-loss medicine, made by Novo Nordisk. It works in a similar way and is also available on private prescription in the UK. Some people may find it easier to access or afford than Mounjaro, depending on the dose and provider.
Other options include tablets such as orlistat, as well as lifestyle support services offered by the NHS or local councils. Not all treatments work in the same way, and they’re not right for everyone, so it’s important to get proper advice.
What should you do next?
If you’re using Mounjaro and worried about the cost, speak to your doctor or pharmacist. They can help you review your treatment and talk through other options.
Do not stop your injections suddenly without getting medical advice. A sudden stop can cause your blood sugar or appetite to change quickly, which might affect your health.
You can also ask about getting treatment through the NHS. Weight-loss medicines are only offered on the NHS in certain situations, but your doctor can explain whether you might qualify.
NHS England has announced that some people will now be able to get the Mounjaro jab from their doctor or at a local clinic.
This applies to people who have:
A BMI of 40 or above - or 37.5 if you are from a minority ethnic group.
Four out of five of the following health conditions - type 2 diabetes, high blood pressure, heart disease, high cholesterol, and sleep apnoea.
Patientval för Hälsonyheter

Hälsonyheter
Medicinska cannabisrecept - fakta bakom rubrikerna
Recent Freedom of Information (FOI) data from the NHS Business Services Authority has prompted sensational headlines about a sharp rise in private prescriptions for medical cannabis in the UK. On the surface, the figures look dramatic. Between 2023 and 2024, prescriptions more than doubled, rising from around 283,000 to 659,000. But these numbers need context. Without it, they risk being misunderstood. This article explains what the data does and does not show, why prescribing has increased, and what this means for patients, clinicians and the NHS.
by Kate Thorpe

Hälsonyheter
Ebolautbrott förklarat som en global hälsokris - vad du behöver veta
Världshälsoorganisationen (WHO) har förklarat ebolautbrottet i Demokratiska republiken Kongo som en "folkhälsokris av internationell betydelse", med fall nu bekräftade i grannlandet Uganda. Här är vad du behöver veta.
av professor Alimuddin Zumla
Om recensentenVisa fullständig biografi

Dr Colin Tidy, MRCGP
Allmänläkare, Medicinsk Författare
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr Colin Tidy är en NHS-läkare, baserad i Oxfordshire.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
Next review due: 14 Aug 2025
14 Aug 2025 | Ursprungligen publicerad
Författad av:
Thomas Andrew Porteus, MBCSGranskad av
Dr Colin Tidy, MRCGP
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.
